How inflammation helps blood stem cells with DNMT3A mutations grow
Inflammatory Stress Promotes Clonal Expansion of DNMT3A-mutant HSCs
This work looks at whether inflammatory signals let blood stem cells carrying DNMT3A mutations expand, especially in older adults at risk for blood disorders.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11330471 on NIH RePORTER |
What this research studies
From a patient perspective, researchers want to know why some blood stem cells with DNMT3A changes become more common as people age, focusing on inflammation such as interferon-gamma. They use laboratory models and analysis of blood or stem cell samples to compare how DNMT3A-mutant cells respond to chronic inflammatory signals versus normal cells. Prior work from the lab showed mutant cells resist some harmful effects of inflammation and can gain dominance, and the team will now map the mechanisms behind that resistance and expansion. The goal is to identify points where treatments or lifestyle changes that lower harmful inflammation might prevent clonal growth.
Who could benefit from this research
Good fit: People most relevant to this work would be older adults or patients known to have clonal hematopoiesis or DNMT3A mutations in their blood.
Not a fit: People without DNMT3A mutations or without evidence of clonal hematopoiesis are unlikely to see direct benefit from this research.
Why it matters
Potential benefit: If successful, this work could point to ways to prevent or slow the growth of mutant blood cell clones and reduce risk of progression to blood disorders like myelodysplastic syndromes.
How similar studies have performed: Previous laboratory studies, including work by this group, have shown inflammatory signals like interferon-gamma can favor DNMT3A-mutant cells, but translating these findings into patient therapies is still new.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Challen, Grant Anthony — Washington University
- Study coordinator: Challen, Grant Anthony
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.